Kimberly Nearing

BVCF Management Ltd., founded in 2005 by visionary leaders with strong academic ties to Harvard University, is a dynamic global investment firm focused on the life sciences and healthcare sectors. With nearly two decades of experience, BVCF is known for identifying and backing transformative companies poised to reshape the future of healthcare. Its portfolio includes high-impact investments in cutting-edge companies like BioNTech, solidifying BVCF’s position at the forefront of healthcare innovation. The firm’s investment philosophy centers on partnering with talented entrepreneurs and scientists who are developing pioneering solutions in biotech, pharmaceuticals, and medical technology. BVCF’s global reach and extensive network allow it to unlock opportunities for portfolio companies across multiple geographies, enabling growth and success in competitive markets. Driven by a passion for innovation and excellence, BVCF is more than an investor—it is a catalyst for meaningful change in the healthcare landscape, fostering groundbreaking technologies that address significant global challenges.

At Apotheosis Ventures, we provide fractional Chief Business Officer (CBO) advisory services uniquely tailored to biotech, life sciences, and health tech companies. Our experienced partners bring decades of expertise in business development, capital raising, IPO preparation, and strategic partnerships. We work closely with CEOs and executive teams to unlock value, accelerate growth, and position companies for success across global markets. Expert Services that Deliver Results - Full suite of services designed to help life sciences companies navigate challenges and seize new opportunities: • Capital Formation: From Series A funding to IPO readiness, we develop financing strategies, cultivate relationships with institutional investors, and engage analysts and family offices across the U.S., Europe, and Asia. • Business Development & Strategy: We design and execute global strategies aligned with client goals, including out-licensing, M&A, and asset spinouts. Our network opens doors to high-value partnerships. • Investor Relations & Marketing: We refine corporate messaging and create compelling narratives to boost visibility within the investment community and the biopharmaceutical industry, ensuring clients are top of mind for key decision-makers. • Governance & Risk Management: We provide governance advice and risk management frameworks, often collaborating with boards to ensure compliance and drive sustainable growth. Differentiation In today’s life sciences landscape, securing funding, expanding into new markets, and managing regulatory complexities are critical but challenging. We don’t just offer advisory services—we become trusted partners. Whether leading a fundraising round or preparing for an IPO, we remain laser-focused on helping clients achieve their goals. With a global network in the U.S., Europe, and Asia, we help companies secure pivotal partnerships and capital, positioning them for long-term success.

AsedaSciences is a pioneering innovator at the intersection of chemistry, biology, machine learning and data visualization, providing an integrated platform to support global efforts by scientists to develop safer chemicals. Their 3RnD platform provides cutting-edge solutions that empower researchers across diverse disciplines to translate complex data into rapid decisions, improving productivity. With a dedication to data quality, rigorous validation and collaboration, AsedaSciences is committed to advancing scientific discovery and driving meaningful impact in the global research community.

Expression Therapeutics is a biotechnology company focused on developing gene and protein-based therapies for rare diseases and cancer, with an emphasis on addressing unmet medical needs in hemophilia and oncology. The company leverages proprietary technologies to enhance therapeutic efficacy and improve patient outcomes, targeting multi-billion-dollar markets. In addition to its innovative therapeutic platforms, Expression Therapeutics has established its own manufacturing facility, positioning it for streamlined production and scalability. With near-term revenue potential, the company is well-positioned to make a significant impact in the biopharma sector through its cutting-edge therapies and operational capabilities. Backed by a highly experienced team with deep expertise in biotechnology, gene therapy, and oncology, and with strong connections to Emory University, Expression Therapeutics is at the forefront of advancing novel treatments.

MaveriX Oncology is a biotechnology company based in Palo Alto, California, focused on developing innovative, targeted small-molecule therapeutics for the treatment of solid tumors. The company's proprietary platform, Conditionally Activated-Small Molecule Drug Conjugates (CA-SMDC), is designed to selectively kill cancer cells while minimizing impact on healthy tissues by exploiting unique metabolic conditions in the tumor microenvironment. MaveriX aims to address unmet clinical needs, particularly in cancers that are resistant to chemotherapy and immunotherapy, with their lead candidates targeting both early-stage and metastatic solid tumors. By integrating AI-driven design, the company accelerates the discovery of precision therapies with the potential for both monotherapy and combination therapy approaches

RVF (Rostropovich-Vishnevskaya Foundation) is a global development organization that promotes the health and well being of children in need through partnerships that create sustainable, transformational public health programs. RVF’s Chairman is Ambassador Thomas Pickering, former ambassador to the United Nations. Honorary Advisory Board members include President & Mrs. Jimmy Carter; Her Majesty Queen Sofia of Spain; His Royal Highness, Charles, Prince of Wales; Her Royal Highness Princess Irene of Greece. Supporters and Partners include the Bill & Melinda Gates Foundation; Teresa & H. John Heinz III Charitable Fund; The Marjorie Merriweather Post Foundation; Vira Heinz Foundation; Zayed Bin Sultan Al Nahayan Charitable and Humanitarian Foundation; Pfizer; GlaxoSmith Kline; Merck; Government of Japan; and the National Institute of Health, Norway.

Elpiscience Biopharmaceuticals is a clinical-stage company focused on developing innovative immuno-oncology therapies to treat cancer. Founded in 2017 and headquartered in Shanghai, China, the company is advancing a pipeline of novel molecules that target the tumor microenvironment to enhance the immune system's ability to fight cancer. Their lead candidates, including anti-CD39 monoclonal antibody ES002, aim to transform “cold” tumors into “hot” ones, overcoming resistance to existing therapies. Elpiscience is led by experienced industry professionals, such as co-founders Xiaohui Ji, Ph.D., and Hongtao Lu, Ph.D., and is backed by prominent investors like Lilly Asia Ventures and Hillhouse Capital​

Board of Directors: 2019 - Present Regional Head of NY/NJ/PA: 2018 - Present Member: 2017 - Present The BayHelix Group is an influential invitation-only professional organization of Chinese business leaders shaping the future of the healthcare and life sciences industry in China. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to hundreds of members globally with a strong presence in China and the US. Members include executives of many of the world’s top pharmaceutical and biopharmaceutical companies, venture capital firms, as well as CEOs of private companies in China and the US. BayHelix is a excellent entry point for western business people and investors wanting to expand into the Greater China region.

Cedrus Group is a global investment holding company with expertise in Asset Management, Private Wealth Management, and Investment Banking. The firm is led by seasoned investment management professionals who have held senior-level positions at some of the world’s largest investment firms and have decades of international experience including in the US, China, Asia and the Middle East. Strategically headquartered in Hong Kong, Shanghai, Beijing, Shenzhen, Hainan and Zurich.

Growth stage biotech company. Raised $250 million to support per-IPO companies. Then, the IPO window closed.